Advances in therapy
Cost-Utility Analysis of Subcutaneous Methotrexate in the Treatment of Patients with Rheumatoid Arthritis in the UK.
Matthew Tucker, Johannes Pöhlmann, Kristin Grabe-Heyne, Annelie Wagner, Anja Rasch, Mondher Toumi, Muhammad K Nisar, Richard F Pollock
Published: 202510.1007/s12325-025-03450-x
Abstract
INTRODUCTION: Oral methotrexate is the standard first-line treatment for rheumatoid arthritis (RA), but subcutaneous methotrexate may offer improved efficacy and tolerability and, as a second-line treatment, delay escalation to biologics. This study…
Preview only. Read the full abstract at the source